Carefully selected plant extracts and bioactive compounds may, in selected situations, provide physiological support alongside standard ophthalmic treatments, aiming to modulate oxidative stress and ocular metabolism within personalized medicine pathways.
In ocular tissues exposed to physiological ageing or oxidative overload, research is exploring targeted supportive strategies. The aim of clinical phytotherapy is not to replace evidence‑based therapies or offer “natural cures”, but to assess whether certain phytocomplexes may, in selected cases, support ocular defence mechanisms within a personalized medicine framework, always under specialist supervision.
Tap the cards to see, in a purely illustrative way, how active principles are being studied in relation to different ocular structures. This does not imply therapeutic protocols or treatment recommendations.
Focus: MACULA (supportive, under study)
Focus: OPTIC NERVE / MICROCIRCULATION
Focus: VESSELS & RHODOPSIN
Focus: SYSTEMIC INFLAMMATION
Molecules like Quercetin and Fisetin are known to interact with signalling pathways related to oxidative stress and senescence. Clinical data are still emerging and do not allow strong recommendations; any use should remain cautious, individualised, and carefully weighed against benefits and risks.
The retina has exceptionally high energy demands. Cofactors such as Coenzyme Q10 are being evaluated for potential support to mitochondrial function, yet they cannot replace appropriate management of the primary causes of retinal stress or damage, nor established treatments for specific diseases.
Lipofuscin accumulation is regarded as a marker of reduced intracellular clearance. Specific extracts and dietary patterns (e.g., mild intermittent fasting) are investigated for potential effects on autophagy. These are evolving research areas: any clinical application must be decided by physicians, considering comorbidities and individual vulnerability.
Nutrients such as Astaxanthin have shown nutrigenomic interactions in experimental models, including effects on stress‑response genes (e.g., Sirtuins). While promising, these findings do not justify uncontrolled self‑supplementation; comprehensive clinical assessment and adherence to solid evidence must remain the priority.
Methodological principles for placing phytocomplexes, where appropriate, within personalised medicine, avoiding self‑prescription and over‑simplification.
The effect of some nutrients may vary with circadian rhythms. Certain proposals distinguish more “bioenergetic” molecules for daytime (e.g., Citicoline) and antioxidants and Omega‑3s in the evening. These are orientative patterns only: any chronobiological scheme must be adapted to ongoing therapies, routines and tolerance, avoiding rigid, standardised protocols.
Intestinal absorption is a real limiting factor for many supplements. Using phytocomplexes in the presence of marked dysbiosis or gut inflammation may reduce benefit or increase the risk of side effects. Supplementation makes sense only when embedded in a relatively balanced metabolic context, evaluated and monitored by healthcare professionals.
Medical‑grade phytotherapy requires standardised, titrated extracts with traceable purity and dosage. Even when quality is adequate, dose, combinations and duration must be personalised, avoiding unsupervised stacking of multiple products and self‑directed protocols.
In ophthalmology, high‑quality phytotherapy and nutraceuticals may, in carefully selected circumstances, act as physiological modulators in complex scenarios (inflammation, microcirculation, oxidative stress). They are not emergency treatments and do not replace pharmacological or surgical care; at best, they can be an additional layer within a personalized medicine plan, to be shared and regularly re‑evaluated with the treating specialist.
Any nutritional or phytotherapeutic pathways described here are intended exclusively for educational and physiological support purposes. No “alternative therapies” or self‑prescription schemes are proposed. Any supplementation must be evaluated, prescribed and monitored by a physician within a personalized medicine plan, based on clinical history, instrumental tests (e.g., OCT, fundus examination) and ongoing treatments, and must never replace recommended ophthalmological care.